Geraldine Descamps

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target.

VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target.

Journal: Leukemia

Published: September 20, 2024

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.

Journal: HemaSphere

Published: April 16, 2024

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.

Journal: Blood

Published: June 23, 2023

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.

Journal: Cell death & disease

Published: January 28, 2020

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells.

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells.

Journal: Frontiers in oncology

Published: November 09, 2018

p53 regulates CD46 expression and measles virus infection in myeloma cells.

p53 regulates CD46 expression and measles virus infection in myeloma cells.

Journal: Blood advances

Published: August 21, 2018

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

Journal: Journal of hematology & oncology

Published: July 12, 2018

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.

Journal: International journal of molecular sciences

Published: November 25, 2017

The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation.

The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation.

Journal: British journal of haematology

Published: August 16, 2016

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis.

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis.

Journal: Journal of hematology & oncology

Published: February 25, 2015

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology

Published: December 02, 2014

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.

Journal: Blood

Published: July 10, 2014

Showing 1-12 of 17

Last Updated: 09/26/2026